瘤微环境的细胞动态在非小细胞肺癌中驱动免疫治疗耐药性
Shujie Huang1, Jeff Yat-Fai Chung1, Chunjie Li2
1Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.
Cancer letters
|September 26, 2024
概括
免疫检查点抑制剂 (ICI) 对非小细胞肺癌 (NSCLC) 有希望,但耐药性很常见. 了解瘤微环境的理解
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了非小细胞肺癌 (NSCLC) 治疗.
- 对ICI的初级和二级耐药性在晚期NSCLC中提出了重大临床挑战.
- 瘤微环境 (TME) 极大地影响患者对免疫疗法的反应.
研究的目的:
- 综合审查TME内的免疫细胞和树皮细胞在NSCLC中介ICI耐药性的相互作用作用.
- 阐明TME内的多种细胞相互作用如何促进免疫疗法耐药性.
- 确定新的治疗点和战略,以克服NSCLC中的ICI耐药性.
主要方法:
- 文献综述综合了最近关于NSCLC TME中的细胞相互作用的研究.
- 分析T细胞,B细胞,中性粒细胞,巨细胞和癌症相关纤维细胞 (CAF) 之间的动态相互作用.
- 通过TME组成部分探索T细胞调节的基础机制.
主要成果:
- 构成各种免疫和层细胞的TME显著影响了ICI的疗效.
- 复杂的细胞相互作用,包括由CAF和其他免疫细胞影响的不同T细胞状态,驱动抵抗.
- 了解这些相互作用是预测和克服治疗失败的关键.
结论:
- 在NSCLC中ICI耐药性的多方面的机制与TME细胞交叉声交互密切相关.
- 在TME中针对特定的细胞相互作用提供了增强ICI有效性的有希望的策略.
- 本综述为开发个性化治疗方法提供了见解,以改善NSCLC患者的治疗结果.
更多相关视频
07:36Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
Published on: June 12, 2021
6.4K
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.5K
相关概念视频
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
01:27Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:40Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K